Percheron Therapeutics (ASX:PER) has updated shareholders on its actions following the disappointing result in the Phase 2b trial of its avicursen ...

Percheron Capital is a private equity firm focused on partnering with exceptional teams to build market-leading essential services businesses. The firm’s purpose is to support high-quality ...

Before the invention of the tractor, horses and mules were the main force in agriculture. In 1920, there were over 25 million ...

Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Percheron Therapeutics Limited (PER). However, you won't necessarily see their names in the ...